ERBB2 and breast carcinoma: The former group comprises approximately 7-8% of all luminal samples, and is delineated by the HER2+ status, high tumour grades and NPI, more frequent p53 mutations, worse survival outcomes and a slightly younger patient age, compared to the ordinary-luminal breast cancers.